LONDON, Sept. 23, 2010-The European Medicines Agency today recommended the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim.
134016
European medicines Agency recommends suspension of Avandia, Avandamet and Avaglim
169887
Aventis Pharma launches disposable insulin pen
27686
Team Sky may relax 'zero-tolerance' doping policy
23717
Popular class of diabetes drugs increase risk for bladder cancer
98524
An oral agent for the treatment of moderate to severe psoriasis would earn a higher patient share in the United States than in Europe
87104
Adults with newly diagnosed diabetes at risk of liver disease
106855
Advisers warn on multi-index products
103057
High fat food products to be regulated:
92671
FDA approves Onglyza for Type 2 diabetes
128211
Abbott pulls obesity drug from US market
83928
FDA approves Egrifta for treatment of lipodystrophy in people with HIV
44251
Eli Lilly halts two clinical trials of an experimental Alzheimer's treatment
91207
Us Food and Drug Administration extends action date for dapagliflozin by three months
105609
Germany's Merck KGaA drops ms drug
168915
Weight loss pill could cause liver damage
58902
FDA to review safety of anemia drugs from Amgen and Johnson & Johnson
50817
Lse suspends trading